Medication info

Dongkwang Pregabalin Capsules 25 mg

Prescription medicationHard capsuleExpired
Ingredient · strength
Pregabalin›25mg / 1 capsule
Manufacturer / importer
Dongkwang Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a pale yellow upper part and a white lower part filled with white powder.
Packaging
30 capsules/bottle
Approval status
Expired

MFDS item code 201907775 · Approved 2019.11.06

This product's status changed to Expired on 2024.11.06. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures
Who uses it
Adults · Children
Adult dosage
This medicine is administered orally, with or without food, as pregabalin, in 2 divided doses per day. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be gradually discontinued over a period of at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys in unchanged form. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined by the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) | Total daily dose of pregabalinᵃ Starting dose (mg/day) | Maximum dose (mg/day) | Administration ≥60 | 150 | 600 | BID or TID ≥30-<60 | 75 | 300 | BID or TID ≥15-<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Administered once daily a: The total daily dose (mg/day) should be divided as specified under Administration. b: The supplemental dose refers to a dose administered as a single additional dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
Children's dosage
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients 12-17 years of age: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Dongkwang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures with or without secondary general symptoms
  • fibromyalgia.
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunct to treat partial seizures in epilepsy, regardless of the presence of secondary general symptoms, and is effective for the treatment of fibromyalgia. It is used to improve pain and seizure symptoms in various neurological diseases.

Dosage and Administration

Adult dosage

This medicine is administered orally, with or without food, as pregabalin, in 2 divided doses per day. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be gradually discontinued over a period of at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys in unchanged form. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined by the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) | Total daily dose of pregabalinᵃ Starting dose (mg/day) | Maximum dose (mg/day) | Administration ≥60 | 150 | 600 | BID or TID ≥30-<60 | 75 | 300 | BID or TID ≥15-<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Administered once daily a: The total daily dose (mg/day) should be divided as specified under Administration. b: The supplemental dose refers to a dose administered as a single additional dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.

Children's dosage

Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients 12-17 years of age: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors; therefore, if there are any changes in mood or behavior during treatment, it is essential to inform healthcare professionals immediately. Those who have allergies to any of the ingredients of this drug or have specific genetic disorders such as lactose intolerance should not take this medication. Diabetic patients should be cautious as weight gain may require adjustments to their blood sugar control medications. If symptoms of angioedema, such as swelling of the face or around the mouth, occur, stop taking this medication immediately and seek medical attention. Elderly patients should be particularly careful when starting the medication due to risks of dizziness or drowsiness leading to falls or injuries. Temporary blurred vision or changes in sight may occur during treatment; if such symptoms appear, consult with a healthcare professional. Sudden discontinuation of this medication may lead to withdrawal symptoms such as insomnia, headache, nausea, and anxiety, thus it should be tapered off gradually following medical advice. Patients with a history of substance abuse may have an increased potential for dependence; therefore, caution is advised when taking this medication. Patients with impaired kidney function should have their dosage adjusted, and those with heart disease should use it cautiously. Concurrent use with opioid analgesics may increase CNS depression; thus, caution is warranted with concurrent use of these medications. This medication can cause dizziness and drowsiness, making it advisable to avoid driving or operating machinery until symptoms are confirmed. Pregnant women should avoid taking this medication unless in special circumstances due to potential risks to the fetus, and nursing mothers are advised against its use as it can be transmitted through breast milk. In cases of overdose, symptoms may include confusion, drowsiness, depression, and seizures, and treatment such as hemodialysis may be necessary. Keep this medication out of reach of children, and do not transfer it to other containers, as this might lead to accidents or a decline in quality.

Side effects

  • suicidal impulses
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral swelling
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
Show 171 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like symptoms
  • restlessness
  • pain
  • sweating
  • misuse and abuse
  • dependence
  • increased appetite
  • loss of appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual hypersensitivity
  • agitation
  • mood swings
  • emotional decline
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • loss of impulse control
  • apathy
  • ataxia
  • movement coordination dysfunction
  • balance disorders
  • amnesia
  • attention disorders
  • memory disorders
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myoclonus
  • reflex impairment
  • movement abnormalities
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • activity tremor
  • syncope
  • confusion
  • hypokinesia
  • olfactory abnormalities
  • loss of taste
  • writing disorder
  • diplopia
  • vertigo
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distention
  • constipation
  • dry mouth
  • abdominal bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • joint pain
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • breast discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falling
  • feeling drunk
  • sensory abnormalities
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • tongue swelling
  • itching
  • urinary retention
  • gynecomastia
  • lethargy
  • shock
  • anaphylaxis-like symptoms
  • Stevens-Johnson syndrome
  • erythema multiforme
  • delirium
  • paralysis
  • affective disorder
  • agitation
  • seizures
  • coma

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air or moisture. It is important to maintain storage temperatures between 15 and 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with a pale yellow upper part and a white lower part filled with white powder.

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.